The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France.
Oncologist. 2023 May 8;28(5):433-439. doi: 10.1093/oncolo/oyac262.
There remains a paucity of data regarding the efficacy of immune checkpoint therapy (ICT) combinations ± vascular endothelial growth factor (VEGF) targeted therapy (TT) in translocation renal cell carcinoma (tRCC).
This is a retrospective study of patients with advanced tRCC treated with ICT combinations at 11 centers in the US, France, and Belgium. Only cases with confirmed fluorescence in situ hybridization (FISH) were included. Objective response rates (ORR) and progression-free survival (PFS) were assessed by RECIST, and overall survival (OS) was estimated by Kaplan-Meier methods.
There were 29 patients identified with median age of 38 (21-70) years, and F:M ratio 0.9:1. FISH revealed TFE3 and TFEB translocations in 22 and 7 patients, respectively. Dual ICT and ICT + VEGF TT were used in 18 and 11 patients, respectively. Seventeen (59%) patients received ICT combinations as first-line therapy. ORR was 1/18 (5.5%) for dual ICT and 4/11 (36%) for ICT + VEGF TT. At a median follow-up of 12.9 months, median PFS was 2.8 and 5.4 months in the dual ICT and ICT + VEGF TT groups, respectively. Median OS from metastatic disease was 17.8 and 30.7 months in the dual ICT and ICT + VEGF TT groups, respectively.
In this retrospective study of advanced tRCC, limited response and survival were seen after frontline dual ICT combination therapy, while ICT + VEGF TT therapy offered some efficacy. Due to the heterogeneity of tRCC, insights into the biological underpinnings are necessary to develop more effective therapies.
关于免疫检查点治疗（ICT）联合±血管内皮生长因子（VEGF）靶向治疗（TT）在肾细胞癌转移（tRCC）中的疗效数据仍然有限。
这是一项在美国、法国和比利时的 11 个中心进行的接受 ICT 联合治疗的晚期 tRCC 患者的回顾性研究。仅纳入经荧光原位杂交（FISH）证实的病例。通过 RECIST 评估客观缓解率（ORR）和无进展生存期（PFS），并通过 Kaplan-Meier 方法估计总生存期（OS）。
共确定了 29 例患者，中位年龄为 38 岁（21-70 岁），男女比例为 0.9:1。FISH 显示 TFE3 和 TFEB 易位分别在 22 例和 7 例患者中发现。18 例患者接受双 ICT，11 例患者接受 ICT+VEGF TT。17 例（59%）患者接受 ICT 联合治疗作为一线治疗。双 ICT 的 ORR 为 1/18（5.5%），ICT+VEGF TT 为 4/11（36%）。在中位随访 12.9 个月时，双 ICT 和 ICT+VEGF TT 组的中位 PFS 分别为 2.8 和 5.4 个月。双 ICT 和 ICT+VEGF TT 组的中位 OS 分别为转移性疾病的 17.8 和 30.7 个月。
在这项关于晚期 tRCC 的回顾性研究中，一线双 ICT 联合治疗后观察到有限的反应和生存，而 ICT+VEGF TT 治疗提供了一些疗效。由于 tRCC 的异质性，有必要深入了解其生物学基础，以开发更有效的治疗方法。
